DexCom Stock: Is DXCM Underperforming the Healthcare Sector?

Based in San Diego, California, DexCom, Inc. (DXCM) is a medical technology company and pioneer in continuous glucose monitoring. With a market capitalization of $33.2 billion, the company develops innovative CGM systems that provide real-time glucose data, helping people with diabetes better monitor and manage their condition while supporting informed healthcare decisions.

Companies worth between $10 billion and $200 billion are generally classified as “large-cap stocks,” and DexCom fits this description, with its market capitalization reflecting its substantial size and established position within the healthcare sector. DexCom’s competitive edge lies in its innovative continuous glucose monitoring technology and strong reputation for accuracy and reliability. Its CGM systems integrate with insulin pumps, while robust revenue growth, improving profitability, and a strong cash position provide the company with flexibility to invest in innovation and expand its market presence.

DXCM has slipped 5.1% from its 52-week high of $92.59, reached on August 24, 2026. Over the past three months, DXCM stock has climbed 21.1%, outperforming the State Street Health Select Sector SPDR ETF (XLV), which has gained 12.7% over the same period.

Shares of DXCM have climbed 32.4% year-to-date, significantly outperforming XLV’s 10.8% gain over the same period. However, over the past 52 weeks, the stock has gained 8.8%, underperforming the ETF’s 24.8% return.

DXCM has been trading above its 50-day and 200-day moving averages since mid-May, signaling an upward trend.

On July 31, DXCM shares surged about 12% after reporting its Q2 results. The company’s revenue rose 13.1% year over year to $1.31 billion, beating Wall Street forecasts of $1.29 billion, while non-GAAP net income per share of 70 cents surpassed expectations of 61 cents. 

In the competitive healthcare sector, top rival Abbott Laboratories (ABT) has considerably outperformed DXCM, gaining 18.4% over the past year.

Wall Street analysts remain bullish on DXCM’s prospects. The stock has a consensus “Strong Buy” rating from the 29 analysts covering it. The mean price target of $93.11 suggests potential upside of 5.9% from current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.